NXTS vs ARGX vs REGN Stock Comparison

Nexentis Technologies, Argenx Se and Regeneron Pharmaceuticals Prices as of Nov 13, 2026 Peers: Industry group
ARGX Argenx Se
$960.04 +17.3% 1M +7.7% 1Y
Market cap
$59.19B
P/E
31.5x
Revenue (TTM)
$5.82B
Div. yield
–
Biotechnology Healthcare
4 wins

Head to Head

10 decided of 12

Regeneron Pharmaceuticals leads on 6 of the 12 questions below (Regeneron Pharmaceuticals 6, Argenx Se 4). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionNXTSARGXREGNLeader
Larger companyMarket capitalisation $347.67K $59.19B $97.70B REGN
Cheaper on earningsLower P/E, profitable companies only 0.0x 31.5x 20.3x REGN
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 32.8x 14.8x REGN
Faster revenue growthRevenue growth, trailing twelve months -4,237.5% +61.5% +18.6% ARGX
More profitableNet margin, trailing twelve months — 32.3% 28.5% ARGX
Better return on capitalReturn on invested capital — — 11.9% –
Less leveragedLower net debt / EBITDA 0.8x — -1.4x REGN
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -90.3% +7.7% +37.5% REGN
Better 5-year returnAnnualised price return, 5 years -82.4%/yr +25.4%/yr +8.7%/yr ARGX
Less volatileAnnualised volatility, 1 year 235.4% 37.7% 33.9% REGN
Higher overall scoreMean of the five percentile scores vs peers 18/100 92/100 73/100 ARGX

Percentile Scorecard

NXTSARGXREGN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisNXTSARGXREGN
Valuation 7 #612 of 660 82 #122 of 660 89 #75 of 660
Growth 6 #585 of 619 96 #27 of 619 50 #308 of 619
Profitability 22 #462 of 595 99 #9 of 595 92 #48 of 595
Financial Health 38 #423 of 683 – 71 #199 of 683
Shareholder Returns – – 63 #170 of 459
Overall 18 92 73
  • NXTS ranked among 695 companies in Pharmaceuticals and Biotechnology
  • ARGX ranked among 695 companies in Pharmaceuticals and Biotechnology
  • REGN ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodNXTSARGXREGNSPY
1 month +229.2%+17.3%+22.8% -2.0%
3 months +12.0%+12.8%+18.9% -2.8%
6 months -52.0%+20.1%+36.8% +2.0%
Year to date -81.8%+14.2%+23.8% +10.6%
1 year -90.3%+7.7%+37.5% +12.2%
3 years -99.6%+96.0%+20.4% +68.1%
3 years, per year -84.2%+25.2%+6.4% +18.9%
5 years -100.0%+210.1%+51.4% +61.4%
5 years, per year -82.4%+25.4%+8.7% +10.1%
10 years -100.0%—+127.6% +248.5%
10 years, per year -61.8%—+8.6% +13.3%

Risk

MeasureNXTSARGXREGNSPY
Volatility, 1Y 235.4%37.7%33.9% 13.6%
Downside volatility, 1Y 158.4%35.2%30.8% 13.9%
Beta vs S&P 500, 1Y 4.330.540.35 1.00
Return / volatility, 1Y -0.380.201.11 0.90
Max drawdown, 5Y -100.0%-38.2%-59.8% -25.4%
From 52-week high -90.5%-9.3%-1.8% -3.2%
52-week high $22.54$1,058.90$973.36 $779.14
52-week low $0.48$663.93$600.66 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleNXTSARGXREGN
P/E now vs peer median 0.0xmedian 17.0x 31.4xmedian 17.0x 20.2xmedian 17.0x
P/S now vs peer median 0.0xmedian 8.4x 10.2xmedian 8.4x 5.8xmedian 8.4x
EV/EBITDA now vs peer median 0.8xmedian 14.6x —median 14.6x 16.7xmedian 14.6x
P/FCF now vs peer median -0.1xmedian 19.0x —median 19.0x 25.4xmedian 19.0x
P/B now vs peer median 0.2xmedian 2.0x —median 2.0x 2.9xmedian 2.0x
PEG now vs peer median 0.00median 0.43 0.30median 0.43 2.23median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsNXTSARGXREGN
Revenue -$8.94M $5.82B $16.90B
Gross profit – $5.24B $14.49B
Operating income -$10.88M $1.74B $4.86B
Net income -$16.14M $1.88B $4.82B
Free cash flow -$4.50M – $3.83B
R&D $798.00K $1.80B $6.60B
EPS (diluted) $-98.21 $28.43 $45.62
Cash & equivalents $7.62M – $3.66B
Total debt $422.00K – $1.99B
Shares (diluted) 163.23K 66.03M 105.60M
Enterprise value -$25.09M $59.19B $63.04B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricNXTSARGXREGN
P/E 0.0x 31.4x 20.2x
P/FCF -0.1x – 25.4x
P/Operating cash flow -0.1x – 20.1x
P/S 0.0x 10.2x 5.8x
P/B 0.2x – 2.9x
P/Tangible book -0.2x – 3.0x
EV/EBITDA 0.8x – 16.7x
EV/EBIT 0.7x 34.1x 18.5x
EV/Revenue 0.9x 10.2x 5.3x
EV/FCF 1.8x – 23.5x
EV/Operating cash flow 1.8x – 18.5x
PEG (3Y EPS CAGR) 0.00 0.30 2.23

Growth

14 metrics
MetricNXTSARGXREGN
Revenue growth (1Y) -4,238% 61.5% 18.6%
Revenue CAGR (3Y) -182.9% 80.5% 8.9%
Gross profit growth (1Y) – 62.2% 19.1%
Gross profit CAGR (3Y) – 80.0% 8.8%
Operating income growth (1Y) -127.3% 120.6% 31.9%
Operating income CAGR (3Y) -23.5% 85.1% 4.8%
Net income growth (1Y) -70.1% 22.5% 5.2%
Net income CAGR (3Y) -42.2% 115.5% 6.5%
EPS growth (1Y) -666.2% 20.9% 6.8%
EPS CAGR (3Y) -52.0% 104.8% 9.0%
Operating cash flow growth (1Y) -62.8% – -4.4%
Operating cash flow CAGR (3Y) -0.4% – -2.5%
Free cash flow growth (1Y) -65.5% – -9.4%
Free cash flow CAGR (3Y) -0.7% – -6.0%

Profitability

14 metrics
MetricNXTSARGXREGN
Gross margin – 90.0% 85.8%
EBITDA margin – – 31.8%
Operating margin – 29.9% 28.8%
Pretax margin – 32.6% 33.7%
Net margin – 32.3% 28.5%
FCF margin – – 22.6%
Operating cash flow margin 49.6% – 28.7%
Return on equity -218.6% – 14.0%
Return on assets -92.0% – 10.6%
Return on invested capital – – 11.9%
Return on capital employed -73.7% – 13.2%
Asset turnover -0.5x – 0.4x
Cash conversion (OCF / net income) 0.3x – 1.0x
Stock comp / revenue -11.0% – 6.0%

Financial Health

11 metrics
MetricNXTSARGXREGN
Debt / assets 2.3% – 4.5%
Debt / equity 0.2x – 0.1x
Net debt / EBITDA 0.8x – -1.4x
Debt / FCF -0.1x – 0.5x
Liabilities / assets 89.8% – 24.6%
Equity / assets 10.2% – 75.4%
Interest coverage – 10,120x 104.2x
Current ratio 3.7x – 3.4x
Quick ratio 3.2x – 2.7x
Cash ratio 3.2x – 1.5x
Altman Z-score -6.11 – 7.73

Shareholder Returns

7 metrics
MetricNXTSARGXREGN
Dividend yield – – 0.4%
Net buyback yield -2,794% – 2.1%
Shareholder yield -2,794% – 2.5%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusNXTSARGXREGN
Forward P/E – 32.8xFY2026 14.8xFY2026
EPS, next fiscal year – $29.27FY2026 $64.62FY2026
EPS growth, next FY – +49.6%FY2026 +45.8%FY2026
EPS growth, the year after – +32.0% +13.6%
Revenue, next fiscal year – $6.16BFY2026 $18.08BFY2026
Revenue growth, next FY – +44.9%FY2026 +26.1%FY2026
Revenue growth, the year after – +24.0% +14.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersNXTSARGXREGN
Held by institutions – 46.1% 66.2%
Institutions holding – 506 1,329
Change in shares held, QoQ – -2.0% +3.8%
Institutions buying – 263 607
Institutions selling – 162 534
Buyers to sellers – 1.62 1.14

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

NXTSARGXREGN
NXTS 1.00 0.17 0.03
ARGX 0.17 1.00 0.20
REGN 0.03 0.20 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, NXTS, ARGX and REGN?

Regeneron Pharmaceuticals (REGN) is the largest by market capitalisation: Nexentis Technologies (NXTS) $347.67K, Argenx Se (ARGX) $59.19B, Regeneron Pharmaceuticals (REGN) $97.70B.

Which stock is cheaper, NXTS, ARGX and REGN?

Regeneron Pharmaceuticals (REGN) trades on the lowest price-to-earnings ratio (Nexentis Technologies (NXTS) 0.0x, Argenx Se (ARGX) 31.5x, Regeneron Pharmaceuticals (REGN) 20.3x). On next year's consensus earnings, Regeneron Pharmaceuticals (REGN) is cheapest (Argenx Se (ARGX) 32.8x, Regeneron Pharmaceuticals (REGN) 14.8x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Argenx Se (ARGX) grew revenue fastest over the trailing twelve months: Nexentis Technologies (NXTS) -4,237.5%, Argenx Se (ARGX) +61.5%, Regeneron Pharmaceuticals (REGN) +18.6%.

Which company is more profitable?

Argenx Se (ARGX) has the highest net margin (Argenx Se (ARGX) 32.3%, Regeneron Pharmaceuticals (REGN) 28.5%).

Which stock has performed better?

Over the past year Regeneron Pharmaceuticals (REGN) returned the most: Nexentis Technologies (NXTS) -90.3%, Argenx Se (ARGX) +7.7%, Regeneron Pharmaceuticals (REGN) +37.5%. Over five years, Argenx Se (ARGX) compounded fastest (Nexentis Technologies (NXTS) -82.4%/yr, Argenx Se (ARGX) +25.4%/yr, Regeneron Pharmaceuticals (REGN) +8.7%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Regeneron Pharmaceuticals (REGN) has been the steadiest (Nexentis Technologies (NXTS) 235.4%, Argenx Se (ARGX) 37.7%, Regeneron Pharmaceuticals (REGN) 33.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, NXTS, ARGX and REGN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Regeneron Pharmaceuticals (REGN) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.